Temprano Alvaro G, Sanchez de Blas Beatriz, Pérez-Melero Concepción, Espinosa-Escudero Ricardo, Briz Oscar, Cinca-Fernando Paula, Llera Lucia, Monte Maria J, Bermejo-Gonzalez Francisco A, Marin Jose J G, Romero Marta R
Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, IBSAL, Salamanca 37007, Spain.
Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid 28029, Spain.
Bioconjug Chem. 2024 Jul 17;35(7):971-980. doi: 10.1021/acs.bioconjchem.4c00168. Epub 2024 Jul 3.
Conventional serum markers often fail to accurately detect cholestasis accompanying many liver diseases. Although elevation in serum bile acid (BA) levels sensitively reflects impaired hepatobiliary function, other factors altering BA pool size and enterohepatic circulation can affect these levels. To develop fluorescent probes for extracorporeal noninvasive hepatobiliary function assessment by real-time monitoring methods, 1,3-dipolar cycloaddition reactions were used to conjugate near-infrared (NIR) fluorochromes with azide-functionalized BA derivatives (BAD). The resulting compounds (NIRBADs) were chromatographically (FC and PTLC) purified (>95%) and characterized by fluorimetry, H NMR, and HRMS using ESI ionization coupled to quadrupole TOF mass analysis. Transport studies using CHO cells stably expressing the BA carrier NTCP were performed by flow cytometry. Extracorporeal fluorescence was detected in anesthetized rats by high-resolution imaging analysis. Three NIRBADs were synthesized by conjugating alkynocyanine 718 with cholic acid (CA) at the COOH group via an ester (NIRBAD-1) or amide (NIRBAD-3) spacer, or at the 3α-position by a triazole link (NIRBAD-2). NIRBADs were efficiently taken up by cells expressing NTCP, which was inhibited by taurocholic acid (TCA). Following i.v. administration of NIRBAD-3 to rats, liver uptake and consequent release of NIR fluorescence could be extracorporeally monitored. This transient organ-specific handling contrasted with the absence of release to the intestine of alkynocyanine 718 and the lack of hepatotropism observed with other probes, such as indocyanine green. NIRBAD-3 administration did not alter serum biomarkers of hepatic and renal toxicity. NIRBADs can serve as probes to evaluate hepatobiliary function by noninvasive extracorporeal methods.
传统血清标志物常常无法准确检测伴随多种肝脏疾病出现的胆汁淤积。尽管血清胆汁酸(BA)水平升高能敏感地反映肝胆功能受损,但其他改变BA池大小和肠肝循环的因素也会影响这些水平。为了通过实时监测方法开发用于体外非侵入性肝胆功能评估的荧光探针,利用1,3 - 偶极环加成反应将近红外(NIR)荧光染料与叠氮功能化的BA衍生物(BAD)偶联。所得化合物(NIRBADs)通过色谱法(FC和PTLC)纯化(>95%),并使用与四极杆飞行时间质谱分析联用的电喷雾电离进行荧光测定、¹H NMR和高分辨质谱表征。通过流式细胞术对稳定表达BA载体NTCP的CHO细胞进行转运研究。通过高分辨率成像分析在麻醉大鼠中检测体外荧光。通过酯(NIRBAD - 1)或酰胺(NIRBAD - 3)间隔基在COOH基团处,或通过三唑连接在3α位置将炔基花青718与胆酸(CA)偶联,合成了三种NIRBADs。NIRBADs被表达NTCP的细胞有效摄取,这一过程受到牛磺胆酸(TCA)抑制。给大鼠静脉注射NIRBAD - 3后,可体外监测肝脏摄取及随后NIR荧光的释放。这种短暂的器官特异性处理与炔基花青718未释放到肠道以及其他探针(如吲哚菁绿)缺乏肝靶向性形成对比。注射NIRBAD - 3未改变肝脏和肾脏毒性的血清生物标志物。NIRBADs可作为通过非侵入性体外方法评估肝胆功能的探针。